1. Petrovic ID, Migliacci J, Ganly I, Patel S, Xu B, Ghossein R, et al. Ameloblastomas of the mandible and maxilla. Ear Nose Throat J. 2018;97:E26-e32.

PMid:30036443

2. Kar IB, Subramanyam RV, Mishra N, Singh AK. Ameloblastic carcinoma: A clinicopathologic dilemma - Report of two cases with total review of literature from 1984 to 2012. Ann Maxillofac Surg. 2014;4:70-7.

https://doi.org/10.4103/2231-0746.133070

PMid:24987603 PMCid:PMC4073467

3. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943-7.

https://doi.org/10.1126/science.275.5308.1943

PMid:9072974 

4. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6:184-92.

https://doi.org/10.1038/nrc1819

PMid:16453012 

5. Zysman MA, Chapman WB, Bapat B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol. 2002;160:795-800.

https://doi.org/10.1016/S0002-9440(10)64902-4

PMid:11891178

6. Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H. PTEN methylation and expression in glioblastomas. Acta Neuropathol. 2003;106:479-85.

https://doi.org/10.1007/s00401-003-0748-4

PMid:12904991 

7. Lu YM, Cheng F, Teng LS. The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review. Sci Rep. 2016;6:32723.

https://doi.org/10.1038/srep32723

PMid:27620353 PMCid:PMC5020353

8. Akca H, Demiray A, Aslan M, Acikbas I, Tokgun O. Tumour suppressor PTEN enhanced enzyme activity of GPx, SOD and catalase by suppression of PI3K/AKT pathway in non-small cell lung cancer cell lines. J Enzyme Inhib Med Chem. 2013;28:539-44.

https://doi.org/10.3109/14756366.2011.654114

PMid:22299584 

9. Nodit L, Barnes L, Childers E, Finkelstein S, Swalsky P, Hunt J. Allelic loss of tumor suppressor genes in ameloblastic tumors. Mod Pathol. 2004;17:1062-7.

https://doi.org/10.1038/modpathol.3800147

PMid:15133474 

10. Scheper MA, Chaisuparat R, Nikitakis NG, Sauk JJ. Expression and alterations of the PTEN / AKT / mTOR pathway in ameloblastomas. Oral Dis. 2008;14:561-8.

https://doi.org/10.1111/j.1601-0825.2007.01421.x

PMid:18826385 

11. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002;8:1178-84.

PMid:12006535

12. Zhu Z, Jia J, Lu R, Lu Y, Fu Z, Zhao L, et al. Expression of PTEN, p27, p21 and AKT mRNA and protein in human BEL-7402 hepatocarcinoma cells in transplanted tumors of nude mice treated with the tripeptide tyroservatide (YSV). Int J Cancer. 2006;118:1539-44.

https://doi.org/10.1002/ijc.21501

PMid:16184552 

13. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13:283-96.

https://doi.org/10.1038/nrm3330

PMid:22473468 

14. Kumamoto H, Ooya K. Immunohistochemical detection of phosphorylated Akt, PI3K, and PTEN in ameloblastic tumors. Oral Dis. 2007;13:461-7.

https://doi.org/10.1111/j.1601-0825.2006.01321.x

PMid:17714348 

15. Dahia PL, FitzGerald MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, et al. A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene. 1998;16:2403-6.

https://doi.org/10.1038/sj.onc.1201762

PMid:9620558 

16. Bouras E, Karakioulaki M, Bougioukas KI, Aivaliotis M, Tzimagiorgis G, Chourdakis M. Gene promoter methylation and cancer: An umbrella review. Gene. 2019;710:333-40.

https://doi.org/10.1016/j.gene.2019.06.023

PMid:31202904 

17. Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler PH, et al. PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer. 2004;112:407-10.

https://doi.org/10.1002/ijc.20447

PMid:15382065 

18. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol. 2005;36:768-76.

https://doi.org/10.1016/j.humpath.2005.05.006

PMid:16084946 

19. Xu WT, Yang Z, Lu NH. Roles of PTEN (Phosphatase and Tensin Homolog) in gastric cancer development and progression. Asian Pac J Cancer Prev. 2014;15:17-24.

https://doi.org/10.7314/APJCP.2014.15.1.17

PMid:24528021 

20. Puerta-Garcia E, Canadas-Garre M, Calleja-Hernandez MA. Molecular biomarkers in colorectal carcinoma. Pharmacogenomics. 2015;16:1189-222.

https://doi.org/10.2217/PGS.15.63

PMid:26237292 

21. Alvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. Mechanisms of PTEN loss in cancer: It's all about diversity. Semin Cancer Biol. 2019;59:66-79.

https://doi.org/10.1016/j.semcancer.2019.02.001

PMid:30738865 

22. Narayan B, Urs AB, Augustine J, Singh H, Polipalli SK, Kumar S, et al. Genetic alteration of Exon 5 of the PTEN gene in Indian patients with ameloblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127:225-30.

https://doi.org/10.1016/j.oooo.2018.11.011

PMid:30598407 

23. Huhns M, Salem T, Schneider B, Krohn M, Linnebacher M, Prall F. PTEN mutation, loss of heterozygosity, promoter methylation and expression in colorectal carcinoma: two hits on the gene? Oncol Rep. 2014;31:2236-44.

https://doi.org/10.3892/or.2014.3097

PMid:24647592 

24. Martins FC, Santiago I, Trinh A, Xian J, Guo A, Sayal K, et al. Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol. 2014;15:526.

https://doi.org/10.1186/s13059-014-0526-8

PMid:25608477 PMCid:PMC4268857

25. Turker MS. Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene. 2002;21:5388-93.

https://doi.org/10.1038/sj.onc.1205599

PMid:12154401